In vitro assessment and multicenter cohort study of comparative nephrotoxicity rates associated with colistimethate versus polymyxin B therapy.
about
Critical evaluation of ceftolozane-tazobactam for complicated urinary tract and intra-abdominal infectionsAcinetobacter baumannii: evolution of antimicrobial resistance-treatment optionsTreatment Options for Carbapenem-Resistant Enterobacteriaceae InfectionsPolymyxins: Antibacterial Activity, Susceptibility Testing, and Resistance Mechanisms Encoded by Plasmids or Chromosomes.Validation of a model to predict the risk of nephrotoxicity in patients receiving colistinColistin and polymyxin B: peas in a pod, or chalk and cheese?P-Glycoprotein Induction Ameliorates Colistin Induced Nephrotoxicity in Cultured Human Proximal Tubular CellsIn vitro antibacterial activity of rifampicin in combination with imipenem, meropenem and doripenem against multidrug-resistant clinical isolates of Pseudomonas aeruginosa.Clinical outcomes associated with polymyxin B dose in patients with bloodstream infections due to carbapenem-resistant Gram-negative rodsMulticenter Prospective Cohort Study of Renal Failure in Patients Treated with Colistin versus Polymyxin B.Optimization of Polymyxin B in Combination with Doripenem To Combat Mutator Pseudomonas aeruginosaColistin- and polymyxin-induced nephrotoxicity: focus on literature utilizing the RIFLE classification scheme of acute kidney injury.Adverse reactions associated with systemic polymyxin therapy.To B or not to B, that is the question: is it time to replace colistin with polymyxin B?Strategies for the safe use of colistin.The safety of polymyxin antibiotics.Polymyxin B versus colistin: an update.Good tolerability of high dose colistin-based therapy in patients with haematological malignancies.The growing threat of multidrug-resistant Gram-negative infections in patients with hematologic malignancies.Polymyxin: Alternative Mechanisms of Action and Resistance.Pharmacodynamic and pharmacokinetic considerations in the treatment of critically Ill patients infected with carbapenem-resistant Enterobacteriaceae.Pharmacokinetics/pharmacodynamics of colistin and polymyxin B: are we there yet?Nephrotoxicity of Polymyxins: Is There Any Difference between Colistimethate and Polymyxin B?Development of new polymyxin derivatives for multi-drug resistant Gram-negative infections.Recent advances and perspectives in the design and development of polymyxins.Dosing and Pharmacokinetics of Polymyxin B in Patients with Renal Insufficiency.Polymyxin Resistance in Gram-negative Pathogens.Pharmacokinetic/toxicodynamic analysis of colistin-associated acute kidney injury in critically ill patients.Resurgence of Polymyxin B for MDR/XDR Gram-Negative Infections: An Overview of Current Evidence.Multicenter Clinical and Molecular Epidemiological Analysis of Bacteremia Due to Carbapenem-Resistant Enterobacteriaceae (CRE) in the CRE Epicenter of the United States.Role of Renal Drug Exposure in Polymyxin B-Induced Nephrotoxicity.Predicting the risk of nephrotoxicity in patients receiving colistimethate sodium: a multicentre, retrospective, cohort study.Colistin and Polymyxin B Dosage Regimens against Acinetobacter baumannii: Differences in Activity and the Emergence of Resistance.Colistin-associated Acute Kidney Injury in Severely Ill Patients: A Step Toward a Better Renal Care? A Prospective Cohort Study.Risk factors for nephrotoxicity onset associated with polymyxin B therapy.Risk factors for acute kidney injury (AKI) in patients treated with polymyxin B and influence of AKI on mortality: a multicentre prospective cohort study.Nephrotoxicity in Patients with or without Cystic Fibrosis Treated with Polymyxin B Compared to Colistin.Population pharmacokinetics of polymyxin B in acutely ill adult patients.Population Pharmacokinetics of Intravenous Polymyxin B from Clinical Samples.Population Pharmacokinetics of Polymyxin B.
P2860
Q26747429-DAC39464-7B1B-49BC-9080-7779F3778859Q27015109-8E8969BB-BF0E-48C6-B988-7F8B823B1DC2Q28082546-F3441D78-D9E2-4597-865F-4E7257AEB936Q34552966-191B1F34-AD76-4EC7-B4D5-7DFCB5CC2F6AQ34596336-88FD5221-C528-4231-9D61-D675C0270919Q35008357-0FDF01BE-47B8-4419-947C-F0696B41B921Q35749919-54DF54E8-6AC6-458A-897B-66DDB19F495DQ36110885-B00F387D-8843-42C2-B012-181BD87907A8Q36158501-5F09780A-B6DA-4C80-9020-C6B3EE74B894Q36730174-F328E176-F881-42C7-BF82-172C356994A6Q36887819-454FCCB1-44A0-47C1-9C8C-697C002B89E3Q38252561-DEDCE3A4-6658-475C-8790-825DEF6F5FA9Q38255373-8478EC6D-C63E-4BD9-BC4D-B1A2657BD7D7Q38262873-38B1A1F7-0802-465D-B10E-680DB14BCF41Q38548658-30EA7EAF-8C23-4153-A48E-1FAD3F0E99C0Q38586123-9E13AFA0-473E-475C-9D04-E02ADDDA0625Q38613051-C8BC42B7-8761-4BDC-9F1C-E5A6CF376D06Q38869608-F9DE2372-009B-4679-874A-F8908BE769F2Q38875315-114E3ED6-9830-4F07-A7D3-295108E32FB1Q38922536-DBA43579-7503-495B-ACDA-B90292E8B7C2Q38944862-E2E30191-2C87-4C01-8A6E-64CC56C197ACQ38994000-3921EA6B-DC6B-4A68-AB69-1F46307DCC87Q39043757-A22F49E3-B6B7-42B8-8D9D-1DE5DFF5A7C2Q39078589-49A88D1C-3BBE-442E-946F-2A8365A66352Q39190865-B5F14769-396E-460C-AA98-9F42F6753BBBQ40035349-2B9E1C4F-A372-4A63-8718-71226D1BBDADQ40051834-6A36B351-7246-4771-B1E1-4F4D4D9B9BF2Q40052709-4027A09E-66E9-41FB-83B5-7E3BB9A63517Q40111993-D8CE2374-9D2F-4C21-960A-BDC5A7912EE1Q40342728-2AE2DC4E-B741-48DF-A010-D42E8BE884D9Q40368623-93FCD50B-674A-4E78-BC53-E245B54A2F7EQ40569102-7F35243E-6B5E-4986-B837-B2C2414F0443Q40719307-1B1D48EF-9F1F-48AE-9E9D-552800CAF4A5Q41007716-632CD458-0557-4352-8792-F28D9A81055DQ41477519-82798FA7-944F-4FE7-AE88-F6448A01F0C2Q41532045-6EF28155-2A92-4C64-B832-148140727967Q41695302-35B7AE7F-1613-4FAB-B328-87E6539528CBQ47195590-AA52468E-96D8-4CED-B0A3-FEB999CE5D9FQ47195600-05CFEBB5-3F31-4BB9-9B8C-27806C229345Q47313113-A80DA6B8-6B0B-4509-95FF-F9D779F74A70
P2860
In vitro assessment and multicenter cohort study of comparative nephrotoxicity rates associated with colistimethate versus polymyxin B therapy.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 24 February 2014
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
In vitro assessment and multic ...... te versus polymyxin B therapy.
@en
In vitro assessment and multic ...... te versus polymyxin B therapy.
@nl
type
label
In vitro assessment and multic ...... te versus polymyxin B therapy.
@en
In vitro assessment and multic ...... te versus polymyxin B therapy.
@nl
prefLabel
In vitro assessment and multic ...... te versus polymyxin B therapy.
@en
In vitro assessment and multic ...... te versus polymyxin B therapy.
@nl
P2093
P2860
P356
P1476
In vitro assessment and multic ...... te versus polymyxin B therapy.
@en
P2093
Deborah A Figueroa
Jessica M Cottreau
Nishant Prasad
Patrick M McDaneld
Taijun Yin
Vincent H Tam
William L Musick
P2860
P304
P356
10.1128/AAC.02476-13
P407
P577
2014-02-24T00:00:00Z